Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2014

View Archived Issues

Takeda Pharmaceutical discloses new CH24H inhibitors

Astex Therapeutics patents novel IAP inhibitors for cancer

Novel biomarkers for Cushing's syndrome, HDR syndrome and MEN1 identified

Preclinical and early clinical data presented for prodrug of Debio-1452

Enantiomer switching of an existing drug unveils novel mechanism of action against cancer cells

GSK-2339345 proves safe in phase I trials for chronic cough

Kymab secures funding to advance clinical development of antibody therapeutics

FDA orphan status granted to diazoxide choline

ADC Therapeutics and MedImmune to advance ADCT-401 into clinic

Phase II results presented for relamorelin in chronic constipation, diabetic gastroparesis

Cellceutix reports promising findings for brilacidin in diabetic wound model

Sorrento Therapeutics discloses new antibodies for S. aureus infection

KineMed and CHDI Foundation expand Huntington's disease collaboration

Provista Diagnostics initiates clinical study of blood assay for breast cancer

Senesco Technologies completes acquisition of Fabrus

Agenix to sell its tenofovir prodrug

BioAlliance's Livatag receives FDA fast track designation

Ophthotech licenses ex-U.S. rights to Fovista to Novartis

Bioenergenix discloses novel hPASK inhibitors

Dainippon Sumitomo Pharma synthesizes new mGlu5 receptor modulators

MOR-208 receives FDA and EMA orphan drug designations

AADi in-licenses nanotechnology-based drug

Merck KGaA proposes global alliance against schistosomiasis

GSK and Genmab report topline data from pivotal head-to-head study of ofatumumab

Isis Pharmaceuticals begins phase I study of ISIS-PKK-Rx

Takeda achieves FDA approval for vedolizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...